$16.60
-0.22[-1.31%]
At close: Apr 18
$16.60
0[0.00%]
After Hours: 4:20PM EDT
Denali Therapeutics
(NASDAQ:DNLI)Denali Therapeutics Stock (NASDAQ:DNLI), Analyst Ratings, Price Targets, Predictions
Denali Therapeutics Inc has a consensus price target of $43.4, established from looking at the 40 latest analyst ratings. The last 3 analyst ratings were released from UBS, Goldman Sachs, and HC Wainwright & Co. on April 9, 2024, February 29, 2024, and February 28, 2024. With an average price target of $59 between UBS, Goldman Sachs, and HC Wainwright & Co., there's an implied 255.42% upside for Denali Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
UBS
Goldman Sachs
HC Wainwright & Co.
Wedbush
Citigroup
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Denali Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/09/2024 | DNLI | Buy Now | Denali Therapeutics | $16.60 | 92.77% | UBS | Esther Rajavelu | $70 → $32 | Maintains | Buy | Get Alert |
| 02/29/2024 | DNLI | Buy Now | Denali Therapeutics | $16.60 | 201.2% | Goldman Sachs | Salveen Richter | $73 → $50 | Maintains | Buy | Get Alert |
| 02/28/2024 | DNLI | Buy Now | Denali Therapeutics | $16.60 | 472.29% | HC Wainwright & Co. | Andrew Fein | $105 → $95 | Maintains | Buy | Get Alert |
| 02/28/2024 | DNLI | Buy Now | Denali Therapeutics | $16.60 | 86.75% | Wedbush | Laura Chico | → $31 | Reiterates | Outperform → Outperform | Get Alert |
| 02/22/2024 | DNLI | Buy Now | Denali Therapeutics | $16.60 | 532.53% | HC Wainwright & Co. | Andrew Fein | → $105 | Reiterates | Buy → Buy | Get Alert |
| 12/13/2023 | DNLI | Buy Now | Denali Therapeutics | $16.60 | 92.77% | Citigroup | David Hoang | → $32 | Initiates | → Buy | Get Alert |
| 11/20/2023 | DNLI | Buy Now | Denali Therapeutics | $16.60 | 68.67% | JP Morgan | Jessica Fye | → $28 | Reinstates | → Overweight | Get Alert |
| 11/08/2023 | DNLI | Buy Now | Denali Therapeutics | $16.60 | 86.75% | Wedbush | Laura Chico | → $31 | Reiterates | Outperform → Outperform | Get Alert |
| 10/24/2023 | DNLI | Buy Now | Denali Therapeutics | $16.60 | 110.84% | Cantor Fitzgerald | Charles Duncan | $85 → $35 | Assumes | → Overweight | Get Alert |
| 09/06/2023 | DNLI | Buy Now | Denali Therapeutics | $16.60 | 128.92% | B. Riley Securities | Mayank Mamtani | → $38 | Initiates | → Buy | Get Alert |
| 08/31/2023 | DNLI | Buy Now | Denali Therapeutics | $16.60 | 532.53% | HC Wainwright & Co. | Andrew Fein | → $105 | Reiterates | Buy → Buy | Get Alert |
| 08/31/2023 | DNLI | Buy Now | Denali Therapeutics | $16.60 | 412.05% | Cantor Fitzgerald | Charles Duncan | → $85 | Reiterates | Overweight → Overweight | Get Alert |
| 08/22/2023 | DNLI | Buy Now | Denali Therapeutics | $16.60 | 412.05% | Cantor Fitzgerald | Charles Duncan | → $85 | Reiterates | Overweight → Overweight | Get Alert |
| 08/10/2023 | DNLI | Buy Now | Denali Therapeutics | $16.60 | 412.05% | Cantor Fitzgerald | Charles Duncan | → $85 | Reiterates | Overweight → Overweight | Get Alert |
| 08/09/2023 | DNLI | Buy Now | Denali Therapeutics | $16.60 | 86.75% | Wedbush | Laura Chico | $37 → $31 | Maintains | Outperform | Get Alert |
| 08/09/2023 | DNLI | Buy Now | Denali Therapeutics | $16.60 | 532.53% | HC Wainwright & Co. | Andrew Fein | → $105 | Reiterates | Buy → Buy | Get Alert |
| 06/22/2023 | DNLI | Buy Now | Denali Therapeutics | $16.60 | 412.05% | Cantor Fitzgerald | Charles Duncan | → $85 | Reiterates | Overweight → Overweight | Get Alert |
| 06/21/2023 | DNLI | Buy Now | Denali Therapeutics | $16.60 | 532.53% | HC Wainwright & Co. | Andrew Fein | → $105 | Reiterates | Buy → Buy | Get Alert |
| 06/06/2023 | DNLI | Buy Now | Denali Therapeutics | $16.60 | 309.64% | Oppenheimer | Jay Olson | $70 → $68 | Maintains | Outperform | Get Alert |
FAQ
What is the target price for Denali Therapeutics (DNLI)?
The latest price target for Denali Therapeutics (NASDAQ: DNLI) was reported by UBS on April 9, 2024. The analyst firm set a price target for $32.00 expecting DNLI to rise to within 12 months (a possible 92.77% upside). 21 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Denali Therapeutics (DNLI)?
The latest analyst rating for Denali Therapeutics (NASDAQ: DNLI) was provided by UBS, and Denali Therapeutics maintained their buy rating.
When was the last upgrade for Denali Therapeutics (DNLI)?
There is no last upgrade for Denali Therapeutics.
When was the last downgrade for Denali Therapeutics (DNLI)?
There is no last downgrade for Denali Therapeutics.
When is the next analyst rating going to be posted or updated for Denali Therapeutics (DNLI)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Denali Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Denali Therapeutics was filed on April 9, 2024 so you should expect the next rating to be made available sometime around April 9, 2025.
Is the Analyst Rating Denali Therapeutics (DNLI) correct?
While ratings are subjective and will change, the latest Denali Therapeutics (DNLI) rating was a maintained with a price target of $70.00 to $32.00. The current price Denali Therapeutics (DNLI) is trading at is $16.60, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.